Transbiohope | BH-Pilot clinical study results will be presented at the 27th International Congress of The Transplantation Society
Transbio project, oriented to the development of an in vitro diagnostic kit for the treatment of chronic rejection with immunosuppressants. H2020 program of the European Union
"trasplante riñón” “diagnóstico in vitro” “in vitro diagnosis” “trasplante renal” “H2020” “European Commission project” “renal transplant” “kidney transplant” “start-up” “Tres Cantos” “biomedicina” “biomedicine” “biotechnology” “immunobiogram” “inmunobiograma” “tratamiento inmunosupresores” “Treatment with immunosuppressants”
16176
post-template-default,single,single-post,postid-16176,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive
 

BH-Pilot clinical study results will be presented at the 27th International Congress of The Transplantation Society

BH-Pilot clinical study results will be presented at the 27th International Congress of The Transplantation Society

On Tuesday 3th of July at the 27th International Congress of The Transplantation Society (TTS 2018), the promising final Immunobiogram results coming from BH-Pilot clinical study will be presented in a lunch&learn  session by Dr. Julio Pascual, Head of Nephrology Department in Hospital del Mar, Barcelona, and Dr. Isabel Portero, Biohope CEO, titled: Immunobiogram® a novel Precision Medicine Tool to help guidance of immunosuppression in Renal Transplantation. Results of “BH-Pilot” proof-of-concept clinical study

“BH-Pilot” was a clinical study performed in 2017 in patients with a renal transplantation.  Final results coming from the 70 patients included demonstrate that INMUNOBIOGRAM® provides an individualized patient response pattern to immunosuppressive medication. INMUNOBIOGRAM® could contribute in the future to identify the sensitivity/resistance profile of each patient to immunosuppressants and help physicians to take informed decisions in the clinical practice to minimize the risk of allographic transplant rejection.